{"id":"W2979809231","doi":"10.1182/blood.v124.21.519.519","title":"Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML)","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ponatinib; Medicine; Imatinib; Internal medicine; Imatinib mesylate; Myeloid leukemia; Clinical endpoint; Nilotinib; Oncology; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003915266,0.0005719347,0.00137476,0.0004528165,0.00005442689,0.0000217852,0.0002841825,0.0001978842,0.0002673196],"category_scores_gemma":[0.000230476,0.0004406217,0.0001247094,0.0007798557,0.0002237292,0.0002009129,0.00007001464,0.0005142928,0.00003018552],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004584434,"about_ca_system_score_gemma":0.004158864,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000807854,"about_ca_topic_score_gemma":0.00179391,"domain_scores_codex":[0.9962512,0.0002094237,0.001092349,0.0007739323,0.0008561903,0.0008169197],"domain_scores_gemma":[0.9977112,0.0003427099,0.0005578778,0.0009508227,0.0001537169,0.0002836165],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4589214,0.1045116,0.2876254,0.003284295,0.002895425,0.001850207,0.004897117,0.003192501,0.01015432,0.000306624,0.0005729884,0.1217882],"study_design_scores_gemma":[0.9255937,0.03136735,0.03171838,0.00143994,0.0005004991,0.0000240501,0.00005069575,0.002693948,0.00571754,0.00001636838,0.000407353,0.0004701055],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9946512,0.0002736202,0.00005670717,0.00005873822,0.00008654508,0.003679289,0.00007659066,0.00007945392,0.001037885],"genre_scores_gemma":[0.9972504,0.00003620174,0.001272582,0.0000647716,0.0002683943,0.0004029733,0.0005164294,0.0001009387,0.00008732965],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4666724,"threshold_uncertainty_score":0.9998046,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01277370156602501,"score_gpt":0.2755707507136372,"score_spread":0.2627970491476121,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}